Evidence map›Paper›PMID 37209580›Full record

ReviewSeminars in nephrology2022

Transplant Onconephrology: An Update.

Christopher D Blosser, Andrew J Portuguese, Cecilia Santana, Naoka Murakami

Open access · greenAbstract readReview
In one paragraph

Review in Seminars in nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Christopher D BlosserDivision of Nephrology, University of Washington, Seattle, WA; Division of Nephrology, Seattle Children's Hospital, Seattle, WA. Electronic address: chrisbl@uw.edu.
Andrew J PortugueseFred Hutchinson Cancer Center, Seattle, WA.
Cecilia SantanaThe Rogosin Institute, New York, NY.
Naoka MurakamiDivision of Renal Medicine, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA.
Fred Hutch Cancer Center · USHarvard University · USSeattle Children's Hospital · USThe Rogosin Institute · US

Funding

RESEARCH TRAINING IN HEMATOLOGYT32HL007093 · NHLBI · UNIVERSITY OF WASHINGTON · PI Janis L Abkowitz · 1985 to 2026
$13.9M
Protection of kidney from autoimmunity by modulating co-stimlatory signalingK08DK120868 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI MURAKAMI, NAOKA · 2019 to 2023
$886k
NHLBI NIH HHS T32 HL007093NIDDK NIH HHS K08 DK120868
6 · The paper itself

Abstract

Transplant onconephrology is a growing specialty focused on the health care of kidney transplant recipients with cancer. Given the complexities associated with the care of transplant patients, along with the advent of novel cancer therapies such as immune checkpoint inhibitors and chimeric antigen-receptor T cells, there is a dire need for the subspecialty of transplant onconephrology. The management of cancer in the setting of kidney transplantation is best accomplished by a multidisciplinary team, including transplant nephrologists, oncologists, and patients. This review addresses the current state and future opportunities for transplant onconephrology, including the roles of the multidisciplinary team, and related scientific and clinical knowledge.

Indexed as

Kidney TransplantationNeoplasmsHumansNephrologistsTransplant Recipientscancerchimeric antigen–receptor T cellimmune checkpoint inhibitorimmunosuppressionimmunotherapykidney transplantTransplant onconephrology

Identifiers

PMID37209580
PMCPMC10330527
OpenAlexW4377078858

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.